Immuneering Corporation (NASDAQ:IMRX), a clinical-stage biotechnology company specializing in oncology treatments, announced Thursday that it has entered into a definitive securities purchase agreement with a group of leading institutional and accredited investors. The private placement is expected to generate approximately $25 million in gross proceeds, before fees and expenses. The deal is slated to close around August 26, 2025, subject to customary conditions.
CEO Highlights Clinical Progress
“We are excited to announce updated Overall Survival (OS) and Progression-Free Survival (PFS) data from our ongoing Phase 2a trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients, planned in the coming weeks. In June, we reported an exceptional 94% OS observed at 6 months in first-line pancreatic cancer patients treated with atebimetinib in combination with mGnP. To put that in perspective, in the pivotal study of standard of care GnP, the 6-month OS was only 67%, and dropped rapidly to only 50% by 8.5 months,” said Ben Zeskind, Ph.D., Co-founder and Chief Executive Officer of Immuneering.
He added: “Our exceptional 6-month overall survival data in first-line pancreatic cancer patients generated strong interest from leading pharmaceutical companies and top-tier investors, including the visionary investors participating in today’s financing. We are developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, which we believe represent an important new way to keep cancer patients alive and help them thrive. The proceeds from this financing will help support our ongoing efforts to bring atebimetinib, our Deep Cyclic Inhibitor of MEK in the MAPK pathway, to as many cancer patients as possible as quickly as possible.”
Deal Structure
Under the terms of the agreement, investors will purchase 6,329,113 unregistered shares of Immuneering’s Class A common stock at $3.95 per share. Certain investors will instead receive pre-funded warrants priced at $3.949 per share, which reflects the stock purchase price minus the $0.001 per share exercise fee.
The transaction also includes warrants to purchase 2,848,096 shares of Class A common stock at an exercise price of $5.50 per share. These warrants will remain exercisable for five years once the underlying securities are registered for resale. The purchase price represents a roughly 15% premium over Immuneering’s last reported closing price on August 20, 2025. Investors in the deal will also receive registration rights.
About Immuneering
Immuneering is advancing a pipeline of oncology therapies built around its proprietary “Deep Cyclic Inhibitors” platform. Its lead candidate, atebimetinib (IMM-1-104), is an oral, once-daily MEK inhibitor designed to improve durability, tolerability, and expand use in MAPK pathway-driven tumors such as pancreatic cancer. The drug is currently in a Phase 2a trial involving patients with advanced solid tumors.
The company’s broader pipeline includes early-stage programs targeting additional cancer indications. More information is available at www.immuneering.com.
Immuneering Corporation stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.